Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Smith & Nephew plc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $84.61, while Smith & Nephew plc trades at $29.78 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| ROBO | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $38.70 |
52-Week Low | $62.34 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $84.50, up 1.25% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights robotics stocks rallying, with thematic ETF interest growing in AI and automation. The stock shows strong momentum but lacks disclosed financial ratios, requiring deeper fundamental verification.
Outlook is cautiously optimistic due to sector tailwinds from AI infrastructure growth, but risks include cyclical exposure and high valuations. Investors should assess upcoming earnings for profitability metrics, as current data gaps limit fundamental clarity amid positive market sentiment.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
